Steffi Oesterreich

Has grant

UPMC Hillman Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Role of Loss of E-cadherin in lobular breast cancer phenotypes

Open Date: 2022-10-01

Close Date: 2023-09-30

Grant: Close

Heterogeneity of invasive lobular breast cancer

Open Date: 2021-10-01

Close Date: 2022-09-30

Grant: Close

Heterogeneity of Invasive Lobular Breast Carcinoma

Open Date: 2020-10-01

Close Date: 2021-09-30

Grant: Close

Endocrine Resistant Invasive Lobular Breast Cancer

Open Date: 2018-10-01

Close Date: 2019-09-30

Grant: Close

Endocrine resistant Invasive Lobular Cancer

Open Date: 2014-10-01

Close Date: 2015-09-30

Articles (35)

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with high metastatic potential, limited treatment options, and low patient survival rates. By combining functional proteomic and genomic approaches, we identified an oncogenic transcriptional network in mesenchymal and invasive TNBC involving the glucocorticoid receptor, GATA6, MYC, and AP-1 transcription factors. Although these transcription factors bound extensively to shared enhancers, they utilized different enhancer repertoires from this shared enhancer pool to drive distinct downstream oncogenic pathways. The SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex was a common gatekeeper of chromatin access for these transcription factors, and SWI/SNF inhibition decommissioned the distinct enhancer networks and protumorigenic gene programs they control. Consistently, SWI/SNF inhibition repressed TNBC proliferation, glucocorticoid-induced chemoresistance, and invasion in vitro and suppressed tumor growth and metastasis in vivo . Thus, these findings indicate that SWI/SNF-mediated chromatin remodeling drives TNBC progression, positioning SWI/SNF as a promising therapeutic target in this disease. Significance: Inhibition of SWI/SNF-mediated chromatin remodeling represses multiple cancer hallmarks in triple-negative breast cancer by blocking chromatin access for diverse transcription factors at shared enhancers, demonstrating the therapeutic potential of targeting DNA access.

Year:

2025

S1. FOXA1 redistribution in ESR1 mutant cells causes distinct ER-FOXA1 interaction.S2. FOXA1 gained peaks annotated genes are significantly associated with novel target genes.S3. FOXA1 redistribution in ESR1 mutant cells confers potential RXR binding sites.S4. RXR agonist LG100268 can promote colonization and growth of ESR1 mutant cells.S5. Clonogenic survival assay and 2D growth assay to test RXR response in Park and Gertz MCF7 cell models.S6. FOXA1 knockdown drastically attenuated the base line growth of both ESR1 WT and mutant cells.S7. RXR antagonist HX531 can inhibit the response of ESR1 mutant cells to RXR agonist.S8. RXR antagonist HX531 can inhibit the basal and agonist promoted growth of IPM-PDXO-073 organoid.

Year:

2025

PURPOSE We performed spatial transcriptomics of estrogen receptor (ER)–negative, ER-low, and ER-high tumor regions of breast cancers that were intermediate (10%-60%) ER-positive by immunohistochemistry to better understand the intratumor heterogeneity in ER expression and to elucidate whether cells of different molecular subtypes (ie, Luminal A [LumA], Luminal B [LumB], human epidermal growth factor receptor 2–enriched, or Basal-like) can coexist in the same tumor. METHODS Digital spatial profiling was performed on 10 ER-heterogeneous (10%-60% ER+) and 10 ER-high (>60% ER+) primary breast cancers using the NanoString GeoMx platform with the Human Whole Transcriptome Atlas probe set. RESULTS LumA and LumB molecular subtypes were intermixed, but there were no Basal-like populations in these ER-heterogeneous tumors. The ER-negative (ER–) regions were LumB-like and showed lower expression of ESR1 and endocrine therapy sensitivity gene signatures but higher expression of immune-related genes and higher recurrence scores, indicating a more endocrine-resistant but chemotherapy-sensitive phenotype. We also found that ESR1 strongly positive cells enriched after preoperative chemotherapy in clinical trial tissues. CONCLUSION This study demonstrates mixed Lum-A and Lum-B molecular subtypes within ER-intermediate primary breast cancers and reveals that ER– tumor cell populations have molecular features of endocrine resistance but chemotherapy sensitivity. These findings may explain the worse clinical outcomes of patients with ER-heterogeneous breast cancers and suggest benefit from combined endocrine and chemotherapy strategies.

Year:

2025

PURPOSE Despite varying treatment responses and vastly different clinicopathologic characteristics, invasive lobular carcinoma (ILC) is treated similar to other subtypes of breast cancer. Serial personalized and tumor-informed, circulating tumor DNA (ctDNA) analysis may enable real-time treatment monitoring in metastatic ILC (mILC). METHODS In this retrospective analysis of real-world data, we analyzed ctDNA longitudinally in 66 patients with mILC using a clinically validated, personalized, tumor-informed 16-plex polymerase chain reaction-next generation sequencing assay (Signatera). We evaluated the predictive value on survival of a single ctDNA test result and correlated ctDNA detection rates and on-treatment ctDNA dynamics with disease status. RESULTS A total of 355 plasma samples were analyzed from 66 patients with mILC (median age at diagnosis, 62.6 years [range, 32.2-79.7 years]). On treatment, ctDNA dynamics correlated well with clinical response to treatment as assessed by imaging. Ninety-two percent (11 of 12) of patients with either ctDNA decrease (6 of 6) or no change in ctDNA levels (5 of 6) while on treatment showed clinical benefit from their prescribed regimen, whereas only 31% (4 of 13) of patients who showed an increase in their ctDNA had a clinical benefit on imaging. Finally, patients with a positive ctDNA test showed a greater probability of death compared with those with negative results, and the positive predictive value of ctDNA testing continued to increase exponentially with each positive result. Similarly, a negative ctDNA result was associated with 97% overall survival at 6 months and remained high (approximately 90%) at the 12-month follow-up. CONCLUSION Serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring.

Year:

2025

Brain metastases (BrM) occur in 10-15% of patients with estrogen receptor (ER)-positive breast cancer, and remain a significant clinical challenge. While current therapeutic paradigms, including surgical resection and systemic therapy, have efficacy in the management of BrM from ER+BC, median overall survival following the diagnosis of BrM is approximately 18 months. The limited efficacy of current therapies, along with a relative paucity of therapeutic options, highlight the urgent clinical need to identify druggable targets for BrM from ER+BC. We previously identified recurrent overexpression of the receptor tyrosine kinase RET in breast cancer BrM relative to patient-matched primary tumors. The principal ligand for RET, Glial Cell-Derived Neurotrophic Factor (GDNF), is predominately expressed in the brain, where it functions in the maintenance of neurons and multiple glial cell types. Here, we show that increased RET expression and activation correlates with brain metastasis in breast cancer patients. Further, we confirm the role of RET signaling in the promotion of metastatic properties in vitro, including tumor spheroid formation, migration, invasion, and transformation. Using RET-overexpressing and RET-deficient models in four ER+BC cell lines, we demonstrate that RET overexpression enhances activation of RET downstream targets, such as ERK and AKT, and promotes metastatic phenotypes in in vitro , ex vivo and in vivo assays. Importantly, we demonstrate that the phenotypic effects of GDNF-mediated RET signaling can be abrogated by administration of Pralsetinib, a highly potent RET-selective kinase inhibitor. Using an ex vivo mouse brain slice co-culture model, we further demonstrate that RET overexpression in breast cancer cell lines potentiates their colonization and invasion into the brain tissues, which are reduced in RET-knockdown cell lines. RET overexpression facilitates brain colonization of breast cancer cells in vivo and is associated with reduced survival. Using proteomic analyses, we identify novel GDNF-mediated signaling pathways in breast cancer cell line models, including PLCγ, P70S6K, STAT3 and CREB. RET-mediated activation of this range of downstream targets is sensitive to inhibition by Pralsetinib. In sum, this study identifies and characterizes RET as a targetable driver of breast cancer brain metastasis, and further describes the action of Pralsetinib in ER-positive breast cancer cell lines, providing insights to improve current targeted therapies for patients with breast cancer brain metastasis. Bullet points RET expression and activation are increased in breast cancer brain metastases. Pralsetinib potently inhibits RET activation in RET overexpressing and in non-overexpressing breast cancer cell line models. RET overexpression and activation confers pro-metastatic properties including cell proliferation, colonization, migration and invasion in vitro and in ex vivo brain co-culture and enhances brain colonization of breast cancer cells in vivo . GDNF increases activation of ERK1/2, AKT, PCLγ, P70S6K, STAT3, and CREB in RET overexpressing MCF-7 cells. CREB or P70S6K knockdown attenuates GDNF stimulated activation of RET downstream targets and cell migration. Graphical Abstract

Year:

2025

Background Dysplastic tissue architecture in estrogen receptor-positive (ER+) breast cancer across therapy-naïve and therapy-exposed cancer tissues presents unique challenges in the analysis of spatial transcriptomics. Many tools for deconvolution are developed on well-structured tissue architectures such as the 10x Genomics mouse hippocampus dataset. Spatial transcriptomics analysis could offer valuable insights into treatment response, but faces limitations in cellular resolution. Methods To address this problem, we developed CITEgeist, a computational tool for spatial transcriptomic deconvolution using integrated proteomics data from the same slide. Visium Antibody Capture technology was applied alongside our novel algorithm to analyze the tumor microenvironment. We demonstrate the reliability of our method using pre- and post-treatment samples from six breast cancer cases. Results Our approach revealed previously undetectable cellular interactions within the tumor microenvironment. By taking an interoperable approach to software development and grounding our algorithm in interpretable variables, we demonstrate how CITEgeist deconvolution is not only accurate but robust enough to be directly used as input in external analytical tools developed by other research teams. We then applied this approach to a set of specimens from a prospective trial our group ran and further validated the findings in a series of in vitro experiments as a demonstrated use case of the utility, necessity, and flexibility of CITEgeist; and the potential of our method to rapidly translate novel clinical samples to new biological insights. Conclusions CITEgeist addresses a critical technical gap in spatial multi-omics analysis through an integrated, multi-disciplinary approach. This work demonstrates the value of combining clinical, translational, and computational expertise to identify novel mechanisms of treatment resistance, potentially transforming therapeutic strategies for resistant disease.

Year:

2025

Endocrine therapies targeting the estrogen receptor (ER/ ESR1 ) are the cornerstone to treat ER-positive breast cancers patients, but resistance often limits their effectiveness. Notable progress has been made although the fragmented way data is reported has reduced their potential impact. Here, we introduce EstroGene2.0, an expanded database of its precursor 1.0 version. EstroGene2.0 focusses on response and resistance to endocrine therapies in breast cancer models. Incorporating multi-omic profiling of 361 experiments from 212 studies across 28 cell lines, a user-friendly browser offers comprehensive data visualization and metadata mining capabilities ( https://estrogeneii.web.app/ ). Taking advantage of the harmonized data collection, our follow-up meta-analysis revealed transcriptomic landscape and substantial diversity in response to different classes of ER modulators. Endocrine-resistant models exhibit a spectrum of transcriptomic alterations including a contra-directional shift in ER and interferon signalings, which is recapitulated clinically. Dissecting multiple ESR1 -mutant cell models revealed the different clinical relevance of cell model engineering and identified high-confidence mutant-ER targets, such as NPY1R . These examples demonstrate how EstroGene2.0 helps investigate breast cancer’s response to endocrine therapies and explore resistance mechanisms.

Year:

2024

Number of overall 10-year, early (0-5 years), and late (5-10 years) distant recurrences (DR) by prespecified BCI risk groups for patients with N0 tumors, N+ tumors, and the overall cohort (N0 and N+).

Year:

2024

Purpose: The prognostic utility of Breast Cancer Index (BCI) for risk assessment of overall (0–10 years), early (0–5 years), and late (5–10 years) distant recurrence (DR) in hormone receptor–positive (HR+) invasive lobular carcinoma (ILC) was evaluated. Experimental Design: BCI gene expression analysis was performed blinded to clinical outcome utilizing tumor specimens from patients with HR+ ILC from a multi-institutional cohort. The primary endpoint was time to DR. Kaplan–Meier analyses of overall, early, and late DR risk were performed, and statistical significance was evaluated by log-rank test and Cox proportional hazards regression. The prognostic contribution of BCI in addition to clinicopathologic factors was evaluated by likelihood ratio analysis. Results: Analysis of 307 patients (99% ER+, 53% T1, 42% N+, 70% grade II) showed significant differences in DR over 10 years based on BCI risk categories. BCI low- and intermediate-risk patients demonstrated similar DR rates of 7.6% and 8.0%, respectively, compared with 27.0% for BCI high-risk patients. BCI was a significant independent prognostic factor for overall 10-year DR [HR = 4.09; 95% confidence interval (CI), 2.00–8.34; P = 0.0001] as well as for both early (HR = 8.19; 95% CI, 1.85–36.30; P = 0.0042) and late (HR = 3.04; 95% CI, 1.32–7.00; P = 0.0224) DR. In multivariate analysis, BCI remained the only statistically significant prognostic factor for DR (HR = 3.49; 95% CI, 1.28–9.54; P = 0.0150). Conclusions: BCI is an independent prognostic factor for ILC and significantly stratified patients for cumulative risk of 10-year, early, and late DR. BCI added prognostic value beyond clinicopathologic characteristics in this distinct subtype of breast cancer.

Year:

2024

Prognostic performance of BCI for overall 10-year, early (0-5 years), and late (5-10 years) distant recurrence (DR) rate for patients that received adjuvant endocrine therapy in the lobular cohort.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (29)

Jagmohan Hooda

Senior Research Project Director

University of Pittsburgh

UNITED STATES
View details

George Tseng

Professor and Vice Chair for Research

University of Pittsburgh

UNITED STATES
View details

Madeleine Shackleford

Professional Research Assistant

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Lajos Pusztai

Yale University

UNITED STATES
View details

Jason Carroll

Professor of Molecular Oncology

University of Cambridge

UNITED KINGDOM
View details

Junxiao Hu

Assistant Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Jennifer Xavier

University of Pittsburgh

UNITED STATES
View details

Benjamin Bitler

Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Matthew Sikora

Associate Professor

University of Denver

UNITED STATES
View details

Shaymaa Bahnassy

Assistant Professor

Georgetown University

UNITED STATES
View details

Rebecca B Riggins

Professor

Georgetown University

UNITED STATES
View details

Adrian V. Lee

University of Pittsburgh

UNITED STATES
View details

Kornelia Polyak

Dana-Farber Cancer Institute

UNITED STATES
View details

Linda Cook

Professor

University of Colorado Cancer Center

UNITED STATES
View details

Sayali Onkar

Senior Scientist

Mount Sinai Hospital

UNITED STATES
View details

Russell Schwartz

Professor

Carnegie Mellon University

UNITED STATES
View details

Henrik J. Ditzel

Professor, senior consultant, Head of Research

University of Southern Denmark

DENMARK
View details

Jason Gertz

Professor

University of Utah School of Medicine

UNITED STATES
View details

Minetta Liu

Research Collaborator, Professor

Mayo Clinic

UNITED STATES
View details

Daniel D Brown

Senior Research Scientist

University of Pittsburgh

UNITED STATES
View details

Mikkel Terp

Associate Professor

University of Southern Denmark

DENMARK
View details

Ole N. Jensen

University of Southern Denmark

DENMARK
View details

Julia Foldi

Assistant Professor of Medicine

University of Pittsburgh School of Medicine

UNITED STATES
View details

Shalini Rao

Assistant Research Professor

University of Cambridge

UNITED KINGDOM
View details

Zeynep Madak-Erdogan

Professor

University of Illinois at Urbana-Champaign

UNITED STATES
View details

Soleilmane Omarjee

Université Claude Bernard Lyon 1 - Domaine de Rockefeller

FRANCE
View details

Neil Carleton

University of Pittsburgh

UNITED STATES
View details

David Rimm

Professor

Yale University

UNITED STATES
View details

Rasmus Damtoft Siersbæk

Associate Professor

University of Southern Denmark

DENMARK
View details